Odyssey Therapeutics (NASDAQ:ODTX) Upgraded at Zacks Research

Odyssey Therapeutics (NASDAQ:ODTX) was upgraded by equities researchers at Zacks Research to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

ODTX has been the subject of several other reports. Cantor Fitzgerald started coverage on shares of Odyssey Therapeutics in a research note on Tuesday. They set an “overweight” rating for the company. TD Cowen started coverage on shares of Odyssey Therapeutics in a research note on Tuesday. They set a “buy” rating for the company. Wall Street Zen upgraded shares of Odyssey Therapeutics to a “hold” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. started coverage on shares of Odyssey Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $26.00 target price for the company. Finally, Oppenheimer started coverage on shares of Odyssey Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $40.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.00.

Odyssey Therapeutics Stock Up 1.9%

Shares of Odyssey Therapeutics stock opened at $17.00 on Wednesday. Odyssey Therapeutics has a 1-year low of $15.35 and a 1-year high of $20.30.

Insider Activity

In other Odyssey Therapeutics news, major shareholder Tpg Gp A, Llc purchased 1,388,889 shares of the stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $18.00 per share, with a total value of $25,000,002.00. Following the acquisition, the insider directly owned 3,690,146 shares of the company’s stock, valued at $66,422,628. This represents a 60.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Nan (Ln) Li purchased 1,111,111 shares of the stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $19,999,998.00. Following the acquisition, the director directly owned 3,333,516 shares in the company, valued at approximately $60,003,288. This trade represents a 50.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 4,183,777 shares of company stock worth $75,319,986.